HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inter Parfums/Lanvin deal

This article was originally published in The Rose Sheet

Executive Summary

Inter Parfums' Paris-based subsidiary, Inter Parfums S.A., and Lanvin are negotiating a "long-term worldwide license agreement for the creation, development and distribution of fragrance lines under the Lanvin brand name," fragrance company announces June 3. Provisions of the deal would include "an upfront license fee, advertising expenditures and royalty payments" as well as the purchase of existing inventory, firm notes. Proposed transaction is contingent upon a formal agreement between the parties. Lanvin fragrance sales reached $33 mil. in 2003, Inter Parfums says. Planned agreement follows announcement by the French fashion company that it would license its fragrance business and focus on its core ready-to-wear collection due to a difficult economic situation (1"The Rose Sheet" April 12, 2004, In Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel